Infectious Disease · Dengue Therapeutics

Transforming dengue innovation
into global therapeutics.

Aedion Therapeutics is advancing a globally protected antiviral programme for dengue — an infection that affects 400 million people annually with no approved treatment.

Book an Introductory Call View Pipeline Investor Enquiries
Lead Asset
VMD55
Indication
Dengue
Rights
Global Exclusive
Stage
Predecessor Ph III Complete
VMD55 Phase 2a Prep
Founded
2025
Global Dengue Burden
400M
Infections per year worldwide
Source: WHO / Bhatt et al.
100M
Symptomatic cases annually
Source: Brady et al.
500K+
Severe dengue cases each year
Source: WHO
4Bn
People living at risk globally
No approved antiviral treatment exists
Company

Built to advance a specific, urgent mission.

Aedion Therapeutics was founded not to start from zero, but to capture, protect, and advance an existing body of scientific and clinical work. Built around exclusive global rights to VMD55 and grounded in the pioneering research of Professor Max Reynolds, the company is designed to convert promising science into a durable therapeutic asset.

The company combines rigorous IP strategy, disciplined regulatory and clinical execution, and a global commercial structure — credible to institutional investors, strategic partners, and regulators across priority dengue-endemic markets.

"By securing exclusive global rights, centralising know-how, and building a focused regulatory and clinical pathway, Aedion seeks to convert promising science into a durable therapeutic asset."

Lead Asset

VMD55 — a globally protected antiviral programme.

VMD55 is Aedion's lead asset, held under a global exclusive licence and supply framework. The programme builds directly on a completed randomised, double-blind, placebo-controlled Phase III trial in Indonesia, in which patients treated with MAC, the predecessor material to VMD55, cleared dengue virus significantly faster than placebo (p=0.013). Chemical continuity between VMD55 and the trial material has not yet been established; demonstrating it is a programme objective.

Phase III Clinical Evidence

Completed · Indonesia
Study TypePhase III clinical trial — Indonesia
Primary FindingPatients treated with MAC cleared dengue virus significantly faster than placebo (p=0.013); 532 randomised, ~450 analysed per protocol
MechanismNot yet established; a host-response mechanism is a hypothesis the Phase 2a is designed to test
Safety ProfileWell tolerated across three human studies
Next StepPhase 2a of VMD55, designed to test whether the clinical observation holds, and by what mechanism

VMD55 Programme

Lead Asset · Global Exclusive
Asset VMD55
Primary Indication Dengue
Future Expansion Adjacent high-burden viral diseases
Rights Structure Global exclusive licence and supply framework — single global holder
Scientific Origin Pioneering research programme of Professor Max Reynolds
Development Stage Predecessor compound Ph III complete · VMD55 Phase 2a preparation underway
IP Strategy Active protection and strategic expansion of surrounding intellectual property
Quality Standard GMP-aligned international quality development pathway
View Full Pipeline
Investment Rationale

Five reasons Aedion is positioned for long-term institutional value.

01
Scientific Foundation
Built on substantial prior development by Professor Max Reynolds — a meaningfully stronger starting point than a typical early-stage biotech. Prior clinical work gives the programme a head start.
02
Focused Strategy
Purpose-built around dengue. A clear asset focus, defined development plan, and strong rationale for regional execution create clarity for investors and partners.
03
Global Structure
Established to hold exclusive global rights with a coherent legal, IP, and supply framework — designed from the outset for international scalability.
04
Investor Credibility
Company model designed to appeal to institutional investors, strategic partners, and specialist healthcare funders through scientific authenticity and disciplined execution.
05
Scalable Platform
VMD55 is the beginning. Aedion is positioned to become a broader platform in mosquito-borne and viral disease therapeutics, creating long-term strategic optionality.
Aedion is currently accepting enquiries from institutional investors, strategic partners, and specialist healthcare funders.
Investor Information

Advancing a dedicated dengue therapeutic programme at global scale.

Start with a short introductory call. The overview flyer and investor deck are available on request; the data room follows a call and mutual NDA.

Book a Call Request Overview Flyer Request the Deck Data Room Access